Disclaimer:
For research use only. Not for human consumption. Intended for laboratory-based studies by qualified professionals. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
 
Overview:
Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analog engineered for enhanced stability and biological activity. It has been extensively studied for its ability to stimulate endogenous growth hormone (GH) secretion, regulate body composition, and improve metabolic function. Tesamorelin’s unique structure includes a trans-3-hexenoic acid group that significantly increases its resistance to degradation, prolonging its duration of action in research settings.
Mechanism of Action:
Tesamorelin binds to GHRH receptors in the anterior pituitary, stimulating the natural release of GH, which subsequently increases insulin-like growth factor 1 (IGF-1) levels. This GH/IGF-1 axis plays a critical role in protein synthesis, lipid metabolism, and cellular repair. By enhancing lipolysis and fat oxidation, Tesamorelin is particularly relevant in studies exploring visceral fat reduction, metabolic optimization, and hormonal balance.
Research Highlights:
Demonstrated significant increases in GH and IGF-1 in preclinical and clinical studies.
Studied for reduction of visceral adipose tissue (VAT) and improvements in lipid metabolism.
Shown to promote lean muscle preservation and recovery in aging and metabolic models.
Represents a second-generation GHRH analog with improved potency and half-life over Sermorelin.
Specifications:
Form: Lyophilized powder (research-grade)
Purity: ≥98% (HPLC-tested)
Storage: Store refrigerated (2–8 °C), protected from moisture and light.